remimazolam group

Gangnam Severance Hospital · FDA-approved active Small molecule

remimazolam group is a Benzodiazepine Small molecule drug developed by Gangnam Severance Hospital. It is currently FDA-approved for Procedural sedation and anesthesia induction, General anesthesia maintenance. Also known as: remimazolam.

Remimazolam is a benzodiazepine that enhances GABAergic neurotransmission by binding to GABA-A receptors, producing sedation and anxiolysis.

Remimazolam is a benzodiazepine that enhances GABAergic neurotransmission by binding to GABA-A receptors, producing sedation and anxiolysis. Used for Procedural sedation and anesthesia induction, General anesthesia maintenance.

At a glance

Generic name	remimazolam group
Also known as	remimazolam
Sponsor	Gangnam Severance Hospital
Drug class	Benzodiazepine
Target	GABA-A receptor
Modality	Small molecule
Therapeutic area	Anesthesia/Sedation
Phase	FDA-approved

Mechanism of action

Remimazolam potentiates the inhibitory effects of GABA at GABA-A receptors in the central nervous system, leading to sedation, anxiolysis, and muscle relaxation. It is a rapid-onset, short-acting benzodiazepine ester that is quickly metabolized by non-specific esterases, allowing for rapid recovery. This pharmacokinetic profile makes it suitable for procedural sedation and anesthesia induction.

Approved indications

• Procedural sedation and anesthesia induction
• General anesthesia maintenance

Common side effects

• Hypotension
• Respiratory depression
• Headache
• Nausea
• Injection site pain

Key clinical trials

• Effect of Remimazolam and Propofol on Postoperative Delirium (NA)
• Optimal Insertion Time During Remimazolam-Remifentanil Anesthesia for Painless Gastroscopy (NA)
• ED50 of Remimazolam for Anesthesia Induction in Frail Elderly Patients (NA)
• Remimazolam TIVA-Flumazenil Antagonism in Short-duration ENT Surgeries
• Remimazolam for Bronchoscopy in High-Risk Patients (PHASE4)
• A Trial of Remimazolam for Intraoperative Sedation in Pediatric and Adolescent Patients (PHASE2, PHASE3)
• The Effectiveness of Binaural Beats on Midazolam Requirement During Cesarean Section With Spinal Anesthesia (NA)
• Dexmedetomidine Nasal Spray and Pediatric Bronchoscopy (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• remimazolam group CI brief — competitive landscape report
• remimazolam group updates RSS · CI watch RSS
• Gangnam Severance Hospital portfolio CI

Frequently asked questions about remimazolam group

What is remimazolam group?

remimazolam group is a Benzodiazepine drug developed by Gangnam Severance Hospital, indicated for Procedural sedation and anesthesia induction, General anesthesia maintenance.

How does remimazolam group work?

Remimazolam is a benzodiazepine that enhances GABAergic neurotransmission by binding to GABA-A receptors, producing sedation and anxiolysis.

What is remimazolam group used for?

remimazolam group is indicated for Procedural sedation and anesthesia induction, General anesthesia maintenance.

Who makes remimazolam group?

remimazolam group is developed and marketed by Gangnam Severance Hospital (see full Gangnam Severance Hospital pipeline at /company/gangnam-severance-hospital).

Is remimazolam group also known as anything else?

remimazolam group is also known as remimazolam.

What drug class is remimazolam group in?

remimazolam group belongs to the Benzodiazepine class. See all Benzodiazepine drugs at /class/benzodiazepine.

What development phase is remimazolam group in?

remimazolam group is FDA-approved (marketed).

What are the side effects of remimazolam group?

Common side effects of remimazolam group include Hypotension, Respiratory depression, Headache, Nausea, Injection site pain.

What does remimazolam group target?

remimazolam group targets GABA-A receptor and is a Benzodiazepine.

Related

• Drug class: All Benzodiazepine drugs
• Target: All drugs targeting GABA-A receptor
• Manufacturer: Gangnam Severance Hospital — full pipeline
• Therapeutic area: All drugs in Anesthesia/Sedation
• Indication: Drugs for Procedural sedation and anesthesia induction
• Indication: Drugs for General anesthesia maintenance
• Also known as: remimazolam